Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tivantinib

- PMLiVE

NICE backs GSK’s Tafinlar for skin cancer

Joins Yervoy and Zelboraf as a recommended melanoma treatment

Roche - Basel

Strong sales in breast cancer lift Roche revenues

New products Perjeta and Kadcyla lead growth

- PMLiVE

Pfizer’s palbociclib on track for early 2015 launch

Good news for the highly anticipated breast cancer drug

- PMLiVE

One third of UK lung cancer patients die within three months of diagnosis

Study authors say GPs may not notice signs of disease early enough

- PMLiVE

PD1 drugs could end ‘decades of silence’ in bladder cancer therapy

Merck's Keytruda and Roche antibody showing promise

- PMLiVE

Janssen, AZ and Roche at ESMO

Companies present promising data on new cancer drugs

Daiichi Sankyo logo

Japan’s Daiichi Sankyo pays $410m for Ambit Biosciences

Gains rights to cancer drug quizartinib

- PMLiVE

Iressa blood test nears approval in Europe

Diagnostic for AZ's lung cancer drug is less invasive than current tumour biopsy method

Boehringer Ingelheim headquarters

Boehringer signs €465m lung cancer vaccine deal

Licenses CureVac's cancer immunotherapy CV9202

- PMLiVE

Merck Serono pulls development of lung cancer prospect

Ditches tecemotide immunotherapy to focus on anti-PD1

- PMLiVE

Pre-chemotherapy indication for Xtandi in prostate cancer

Astellas drug set to compete with J&J’s Zytiga

- PMLiVE

Pharma spent $342m on journal advertising in first half of 2014

J&J led spending and Invokana was most advertised brand

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links